

ADRI CHAKRABORTY, PhD

Boston, MA | US Permanent Resident | Life Sciences Consultant | R&D and Portfolio Strategy | Program Advisory
215-301-6818 | adri.chakraborty@gmail.com | linkedin.com/in/adri-chakraborty

BACKGROUND

Life sciences consultant and PhD bioanalytical scientist with 10+ years advising biotech, CRO, and non-profit clients on R&D strategy, portfolio decisions, and program execution; Health Sector MBA candidate, BU Questrom. Runs market and evidence assessments and converts analysis into go/no-go and investment recommendations that have steered \$10M+ programs, avoided ~\$500K in low-value spend, and cut leadership decision time ~30%. Manages engagements to scope, budget, and milestones across client teams and vendors.

CONSULTING & ADVISORY EXPERIENCE

Independent AI Consultant (Mercor); Boston, MA Scientific Consultant, AI and Bioanalytical Advisory

April 2026 to Present

- Advise biotech and CRO clients on where AI adds value across bioanalytical and clinical development workflows and where it does not, scoping each engagement to decisions leadership can act on.
- Delivered 3 independent client engagements end to end, on time and within budget, cutting preclinical and bioanalytical data assessment time ~35% and lowering client operating costs.
- Helped clients avoid ~\$500K in low-value spend through go/no-go recommendations on 10+ GenAI programs across drug R&D, clinical-trial design, and bioanalytical reasoning.
- Cut sponsor escalations ~40% and data turnaround ~25% for a CRO client by redesigning LIMS-based data flow and sponsor communication from study start-up through data delivery.
- Achieved 99%+ uptime at go-live on an informatics deployment by leading data migration, testing, UAT, and validation, resolving 30+ configuration issues.

Eutropics Pharmaceuticals; Boston, MA Consultant, Oncology and Translational Programs

July 2024 to January 2025

- Shortened leadership decision time ~30% by synthesizing complex scientific and clinical evidence into a patient-stratification strategy across 4 subgroups for a hematologic oncology program.
- Brought a key therapeutic-candidate decision forward ~2 months by leading development of a novel 4-assay diagnostic package that de-risked the go/no-go call.
- Cut assay turnaround ~30% and strengthened client confidence by optimizing 12-color flow-cytometry panels for 50+ AML/CML patient samples, including CAR-T exhaustion markers, to <15% CV for biomarker and PD evaluation.
- Built a regulatory-ready validation package ~3 months faster by expanding a single-site program into a 3-site external clinical network, tripling the sample base to 200+ and de-risking a key product-validation decision.

Revi LifeSciences; Boston, MA Consultant (Concurrent Appointment)

June 2023 to September 2024

- Kept a \$10M+ ARPA-H-funded program on budget and aligned to milestones by advising client leadership on scope, KPIs, and budget framework, informing 100% of key investment decisions.
- Guided portfolio entry into 3 priority indications by conducting market assessments of the competitive landscape, unmet need, and commercial potential for client leadership.
- Shortened product lead development by ~6 months and expanded capabilities without new in-house investment by serving as scientific lead on 4 academic and industry collaborations, advancing 2 leads to the next development stage.

Boston University School of Medicine; Boston, MA Scientific Advisor, Non-profit and Federally Funded Research (Concurrent Appointment)

January 2020 to October 2024

- Delivered 100% of milestones on budget for a \$1M non-profit and federally funded SSc-ILD program by acting as scientific lead and coordinating scope, timelines, and reporting across 5 partner labs
- Secured 2 follow-on grants by translating program findings into funding cases and progress reporting for non-profit and federal sponsors, including the Scleroderma Foundation.
- Kept sponsors and partner institutions aligned by setting the reporting cadence, milestone tracking, and documentation standards used across the collaboration.

SCIENTIFIC LEADERSHIP EXPERIENCE

Precision for Medicine; Frederick, MD

January 2025 to February 2026

Principal Scientist, Translational Bioanalysis

- Led and mentored a team of 6 scientists, building assay and regulatory expertise and keeping 5 concurrent programs on track.
- Drove PK, ADA, and clinical biomarker decisions across proteins, mAbs, peptides, and viral vectors by designing fit-for-purpose ligand-binding assays (ELISA, MSD/ECL, Simoa) and flow cytometry methods.
- Delivered regulatory-ready clinical biomarker data for 5 oncology and immunotherapy programs with zero audit findings, applying fit-for-purpose validation criteria to GLP/GCP standards.
- Cut sponsor review cycles ~30% by authoring protocols, validation reports, and regulatory documentation that defined method performance and fit-for-purpose acceptance criteria.
- Protected data integrity across 8+ assay transfers and 5+ validations by leading CAPA and OOS/OOT investigations, closing 100% of CAPAs on schedule.

Boston University School of Medicine; Boston, MA

January 2020 to October 2024

Research Assistant Professor (Concurrent Appointment, 2021-2024)

- Linked endothelial injury to fibrotic progression in SSc-ILD by integrating multimodal molecular methods under SOPs, yielding 4 peer-reviewed publications.
- Built translational in vitro and in vivo models of vascular injury and fibrosis, giving the program a reusable platform for target validation across 3 studies.
- Mentored 6 postdocs, students, and technicians, building team capability in vascular biology and lifting lab output with 3 trainee-led publications.

Viska Bio; Boston, MA

June 2021 to June 2024

Senior Scientist, Glioblastoma Research (Concurrent Appointment)

- Led functional characterization of ADC candidates through lead selection, including cytotoxicity and potency assays, and built T-cell/dendritic-cell engager potency assays for biomarker data packages.
- Directed protein-function characterization (aggregation, stability, glycosylation) of vHH nanobody candidates and critical reagents supporting candidate-selection decisions.

Texas A&M University; College Station, TX

July 2017 to November 2020

Postdoctoral Fellow, Obesity and Inflammation Research

- Identified and validated novel neuro-inflammatory and vascular/lymphatic biomarker panels from human adipose punch biopsies, identifying TUG-1 as a key dermal biomarker for use as a clinical trial endpoint.
- Ran clinical operations for the 2019 FDRS Phase-I Lipedema trial, designing clinical protocols, SOPs, and electronic Case Report Forms (eCRFs) to GLP-aligned standards.

EDUCATION

Health Sector MBA (in progress), Boston University, Questrom School of Business; Boston, MA	Expected May 2029
PhD, Cell and Molecular Biology, Saint Joseph's University; Philadelphia, PA	December 2017
MS, Regenerative Medicine, Manipal University	July 2009
BS, Biotechnology, Bangalore University; India	July 2007

SKILLS & ADDITIONAL INFORMATION

Consulting & Strategy: Hypothesis-driven problem solving, market and competitive assessment, unmet need and commercial potential analysis, go/no-go and investment decision support, portfolio and pipeline prioritization

Program & Project Management: Scope, KPI, and budget frameworks, milestone and risk tracking, vendor and partner management, cross-functional team leadership, executive and stakeholder communication

Business Analytics: Quantitative and evidence analysis, KPI definition and tracking, benchmarking, cost and cycle-time analysis, insight synthesis for executive audiences

Generative AI & Digital Delivery: Prompt design and evaluation of AI model outputs, assessment of AI programs for value and feasibility, system testing, UAT, and deployment support

Industry Knowledge: Biotech and pharma R&D from discovery through Phase I, CRO and sponsor operations, GLP/GCP and CAPA, oncology, immunology, fibrotic disease

Tools: Excel, PowerPoint, Word, data visualization (GraphPad Prism, JMP), PubMed

PUBLICATION & AWARDS

15 peer-reviewed publications; presentations and posters in translational immunology and oncology

Scleroderma Foundation Marta Max Fund Award; Pappenheimer Award; Lipedema Foundation Research Award